^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Useful in Certain Circumstances:...Squamous cell carcinoma….Regimen added: cetuximab/nivolumab